Evidence map›Paper›PMID 42112139›Full record

ReviewKidney medicine2026

Research Advances in Rituximab-Resistant Membranous Nephropathy.

Kaiting Li, Wen Liu, Di Wu, Zhihang Su, Qijun Wan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kaiting LiAuthors' Affiliation: Department of Nephrology, the First Affiliated Hospital of Shenzhen University (Shenzhen Second People's Hospital), Shenzhen, China.
Wen LiuAuthors' Affiliation: Department of Nephrology, the First Affiliated Hospital of Shenzhen University (Shenzhen Second People's Hospital), Shenzhen, China.
Di WuAuthors' Affiliation: Department of Nephrology, the First Affiliated Hospital of Shenzhen University (Shenzhen Second People's Hospital), Shenzhen, China.
Zhihang SuAuthors' Affiliation: Department of Nephrology, the First Affiliated Hospital of Shenzhen University (Shenzhen Second People's Hospital), Shenzhen, China.
Qijun WanAuthors' Affiliation: Department of Nephrology, the First Affiliated Hospital of Shenzhen University (Shenzhen Second People's Hospital), Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Membranous nephropathy is an autoimmune disease associated with antibodies against podocyte proteins, and it is the main cause of nephrotic syndrome in adults. Rituximab has now become the first-line treatment for membranous nephropathy, with 80% of patients achieving remission. However, some patients develop drug resistance or experience relapse to rituximab. Potential resistance mechanisms include changes in bioavailability and pharmacokinetics, rituximab internalization by B cells, memory B cells escape from rituximab, generation of anti-rituximab antibodies, impact of phospholipase A

Indexed as

Anti-CD20 monoclonal antibodyglomerulonephritismembranous nephropathyresistancerituximab

Identifiers

PMID42112139
PMCPMC13156742

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.